The Navitor TAVI system is the most recent addition to the company’s extensive structural heart transcatheter portfolio, which provides physicians and patients with less invasive heart disease treatment options.
Abbott announced the launch of Navitor, its next-generation transcatheter aortic valve implantation (TAVI) system, in India for people with severe aortic stenosis who are at high or extreme surgical risk.
The Next-generation Transcatheter Aortic Valve Implantation (TAVI) System
The company is advancing TAVI (also known as TAVR, or transcatheter aortic valve replacement) therapies with the Navitor valve, which features a unique design that prevents blood from leaking around the valve. The Navitor TAVI system is the most recent addition to the company’s extensive structural heart transcatheter portfolio, which provides physicians and patients with less invasive heart disease treatment options.
“For people in India suffering from aortic stenosis and unable to have surgery, this TAVI system offers a safe and effective treatment option. The size ranges allow for patient-specific sizing and optimal valve function,” said Dr Ashok Seth, Chairman, Fortis Escorts Heart Institute and Chairman Fortis Medical Council, New Delhi. “While transcatheter valve replacement has for some time been a standard of care for elderly patients with a narrowing of the aortic valve, this device helps to address challenges we sometimes find in current TAVI systems when we encounter challenging patient anatomies which may lead to potential problems and difficulties.”
New Milestone in Cardiology
According to Dr. Praveen Chandra, Chairman of Interventional & Structural Heart Cardiology at Medanta in Gurgaon, “Aortic valve replacement can be a challenging procedure for people with complications such as age or comorbidities. For such people, a minimally invasive procedure is beneficial. This TAVI system offers important design advantages, helping us with accurate placement and easy access to the coronary arteries for any future interventions if required. These attributes help with better patient outcomes, even across challenging anatomies.”
Navitor includes a one-of-a-kind fabric cuff (NaviSeal) that works with the cardiac cycle to reduce or eliminate paravalvular leak (PVL), a common complication following TAVI procedures. The new device is the only self-expanding TAVI system with intra-annular (within the native valve) leaflets and large frame cells, both of which are intended to improve access to critical coronary arteries and facilitate future interventions to treat coronary artery disease (CAD).
